Sunday, August 04, 2019 6:53:46 AM
LAMEDA, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter ended June 30, 2019, on Wednesday, August 14, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, August 14, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13692586. To access the live webcast, go to the investor relations section on the Company’s website, http://public.viavid.com/index.php?id=135362.
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, diagnostic tests for the early detection and management of cancer, when it is most curable. OncoCyte has developed a proprietary liquid biopsy that can assess the immune system’s response to cancer at its earliest stages. The first application of this liquid biopsy is a blood test in development to aid in the diagnosis of lung cancer and reduce the need for risky and costly diagnostic procedures such as invasive lung biopsies.
Contact
Bob Yedid
LifeSci Advisors, LLC
bob@lifesciadvisors.com
646-597-6989
Source: OncoCyte Corporation
https://finance.yahoo.com/news/oncocyte-report-second-quarter-2019-120000848.html
GO OCX
"PEACE"
Recent OCX News
- Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move • GlobeNewswire Inc. • 06/24/2024 04:41:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:10:27 PM
- Oncocyte Appoints Andrea James as Chief Financial Officer • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/04/2024 09:02:47 PM
- Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study • GlobeNewswire Inc. • 06/03/2024 06:13:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:31 PM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/30/2024 08:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/23/2024 03:26:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/23/2024 04:15:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:18:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:56:24 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/17/2024 09:11:17 PM
- Oncocyte Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- Oncocyte to Announce First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 09:31:11 PM
- PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace • GlobeNewswire Inc. • 05/07/2024 01:19:00 PM
- Oncocyte Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/12/2024 10:00:00 AM
- Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/12/2024 01:46:37 AM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:39:38 PM
- Oncocyte to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:19:59 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM